Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Invested Capital (2019 - 2025)

Historic Invested Capital for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $855.1 million.

  • Harmony Biosciences Holdings' Invested Capital rose 3977.07% to $855.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $855.1 million, marking a year-over-year increase of 3977.07%. This contributed to the annual value of $675.4 million for FY2024, which is 4012.78% up from last year.
  • Harmony Biosciences Holdings' Invested Capital amounted to $855.1 million in Q3 2025, which was up 3977.07% from $791.8 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Invested Capital ranged from a high of $855.1 million in Q3 2025 and a low of $154.0 million during Q3 2021
  • In the last 5 years, Harmony Biosciences Holdings' Invested Capital had a median value of $482.0 million in 2023 and averaged $467.0 million.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Invested Capital crashed by 4771.06% in 2021, and later soared by 12457.38% in 2022.
  • Harmony Biosciences Holdings' Invested Capital (Quarter) stood at $188.5 million in 2021, then soared by 114.76% to $404.8 million in 2022, then rose by 19.06% to $482.0 million in 2023, then soared by 40.13% to $675.4 million in 2024, then grew by 26.61% to $855.1 million in 2025.
  • Its Invested Capital was $855.1 million in Q3 2025, compared to $791.8 million in Q2 2025 and $738.0 million in Q1 2025.